Loading…

medmix AGMEDX.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties
Momentum strong 74
Mkt cap
$494M
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$630,522
20-day average traded
Fwd P/E
19.4×
forward earnings
ROIC−WACC
-1.6 pp
WACC 5.0%
Hurdle
-1 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · CHFCHF 10.10
1D-1.6%
1W-3.3%
1M+0.2%
3M+16.0%
6M+11.2%
YTD-10.1%
1Y+15.7%
ATR %2.8%
52w lowhigh18.3% off high

What medmix does

Employees: 2,574

medmix at a glance

Size medmix (MEDX.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $494M, the 136th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 10.10 on 18 Nov 2026.

Performance Over six months the shares gained 11.2%, against -19.0% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 6.6% over the last twelve months (peer median +7.0%); the operating margin is 6.3% (peer median 2.5%).

Valuation It trades at 19.4× forward earnings against a peer median of 22.4× (4th cheapest of 10).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.6 points below its cost of capital (5.0% WACC).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026MEDX.SW 111Peer median 82
Six months, rebased to 100: medmix against the median of its 20 peers (local-currency closes).

medmix financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 437MCHF 448MCHF 484MCHF 487MCHF 477M
Revenue growth—-7%-1%+2%—
Gross profitCHF 160MCHF 162MCHF 160MCHF 158MCHF 175M
EBITDACHF 78.4MCHF 79.7MCHF 74.3MCHF 68.4MCHF 95.8M
Net incomeCHF 100,000CHF 6.40M-CHF 7.40MCHF 300,000CHF 11.6M
Free cash flowCHF 31.7MCHF 33.3MCHF 48.1MCHF 9.70MCHF 11.2M
Capital expenditureCHF 32.0MCHF 41.1MCHF 48.5MCHF 52.9MCHF 38.6M
Total debtn/aCHF 330MCHF 323MCHF 350MCHF 474M

Quarterly statements and history in the cockpit →

medmix competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%603520688580688298002932688606301033688075AVR7979300639CEVIANGO603309NNNNMDXGRCELMYGNMEDX.SW6-month return →1-month return →
Up and to the right = strong over both horizons. medmix is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×60×6035206885806886063010337979300639CEVI6033094549MEDX.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. medmix is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%688580688606301033688075300246300639CEVI603309300439MDXGMEDX.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. medmix is the large dot.

medmix competitors and peer comparison

How medmix compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

medmix against its 20 peers (data as of 18 Nov 2026)
MeasureMEDX.SWPeer medianRank in peer set
1-month return+0.2%-5.9%4th highest of 21
6-month return+11.2%-19.0%5th highest of 21
Distance from 52-week high-18.3%-40.9%4th highest of 21
Revenue growth (TTM)-6.6%+7.0%5th lowest of 21
Operating margin6.3%2.5%9th highest of 21
Forward P/E19.4×22.4×4th cheapest of 10
Growth the price implies (Req g, 7 yrs)4.5%6.6%5th least demanding of 11
Growth delivered (Del g)+5.0%-0.1%5th highest of 11
Hurdle (Req g minus delivered)-0.5 pp+6.8 pp5th least demanding of 11
ROIC minus cost of capital-1.6 pp-1.6 pp9th lowest of 18
EV / EBITDA8.1×12.5×cheapest of 4
Net debt / EBITDA2.6×-1.7×most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
medmix MEDX.SWSwitzerland$494M+11%-7%6%19.4×4.5%+5.0%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%25.8×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%19.7×20.1%+4.2%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%n/an/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%6.9×-6.5%-4.3%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%22.4×4.3%+24.4%
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%n/a30.8%-18.6%
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%n/an/an/a
Shofu 7979.TJapan$510M+32%+9%14%13.2×n/an/a
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%n/a55.3%-4.7%
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%57.3×0.4%-13.2%
CellaVision CEVI.STSweden$477M+64%+2%23%32.6×7.1%+10.0%
AngioDynamics ANGOUnited States$476M-4%+8%-6%n/an/an/a
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%11.9×-5.9%+7.7%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%n/a6.0%-7.7%
Eiken Chemical 4549.TJapan$466M-20%+4%6%24.5×n/an/a
MiMedx MDXGUnited States$464M-16%-23%-8%n/a10.9%+11.0%
AVITA Medical RCELUnited States$529M+290%+17%-34%n/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%n/an/an/a

Questions

Which companies are medmix's closest peers?
The cockpit's peer set: Zhejiang Starry Pharmaceutical (603520.SS), Nanjing Vishee Medical Technology (688580.SS), Zhejiang Orient Gene Biotech (688298.SS), Wuhan Easy Diagnosis Biomedicine (002932.SZ), Hangzhou Alltest Biotech (688606.SS), Medprin Regenerative Medical Technologies (301033.SZ), Assure Tech (Hangzhou) (688075.SS), Anteris Technologies Global (AVR).
Is medmix expensive compared with its peers?
On forward p/e it trades at 19.4× against a peer median of 22.4×, 4th cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has medmix stock performed?
Over six months to 18 Nov 2026 the shares returned +11.2% against -19.0% for the median peer; over one year +15.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.